Goyal Nishant, Narula Himanshu, Chaturvedi Jitender, Agrawal Sanjay, Dash Chinmaya, Meena Suneeta, Kaistha Neelam
Department of Neurosurgery, All India Institute of Medical Sciences.
Department of Microbiology, All India Institute of Medical Sciences.
Med Mycol J. 2020;61(3):49-53. doi: 10.3314/mmj.20-00005.
Cerebral aspergillosis usually affects immunocompromised hosts and may rarely occur in immunocompetent individuals. Due to its angio-invasive nature, Aspergillus may cause various vascular complications, particularly mycotic aneurysms and infarcts.
A 22-year-old immunocompetent male with diagnosed case of sino-cerebral aspergillosis was taking voriconazole for two months. His headache worsened and repeat imaging showed an increase in the size of the lesion. The patient was managed with right frontal craniotomy and surgical debridement, and voriconazole was continued. After ten days of uneventful post-operative course, the patient developed left-sided hemispheric infarct. The patient is doing well at nine months' follow-up, and he is off voriconazole for three months after the follow-up imaging showed complete resolution of disease.
Treatment of choice for cerebral aspergillosis is voriconazole. Surgical debridement may be a useful adjunct in patients not responding to voriconazole alone.
脑曲霉病通常影响免疫功能低下的宿主,在免疫功能正常的个体中很少发生。由于其血管侵袭性,曲霉菌可能导致各种血管并发症,尤其是霉菌性动脉瘤和梗死。
一名22岁免疫功能正常的男性,被诊断为鼻窦-脑曲霉病,已服用伏立康唑两个月。他的头痛加重,重复影像学检查显示病变大小增加。患者接受了右额开颅手术和手术清创,并继续服用伏立康唑。术后经过十天平稳病程,患者发生左侧半球梗死。在九个月的随访中患者情况良好,在随访影像学显示疾病完全消退后,他停用伏立康唑三个月。
脑曲霉病的首选治疗药物是伏立康唑。对于单独使用伏立康唑无反应的患者,手术清创可能是一种有用的辅助治疗方法。